News & Events about Codiak Biosciences Inc.
Globe Newswire
2 months ago
CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that management will be participating in the 5th Annual ...
Globe Newswire
2 months ago
exoASO-STAT6 demonstrated durable pharmacokinetic/pharmacodynamic profile in preclinical models;biomarkers with clinical translational potential identified, providing a rationale for selecting cancer subtypes for treatment with exoASO-STAT6 Systemically administered exoASO-C/EBP demonstrated extra-...
Globe Newswire
4 months ago
CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK) (Codiak), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, announced today the pricing of its underwritten public offering of ...
Globe Newswire
5 months ago
Enrollment continues in Phase 1 clinical trial of IV-administered exoASO-STAT6 in patients with advanced hepatocellular carcinoma Prioritizing vaccine program funded by CEPI and advancement of engEx-AAV for gene delivery Plans to initiate Phase 2 studies of exoSTING and exoIL-12 paused Codiak ...
Thinking about buying stock in Endo International, FuelCell Energy, Cassava Sciences, Codiak BioSciences, or Teva Pharmaceutical? Thinking about buying stock in Endo International, FuelCell Energy, Cassava Sciences, Codiak BioSciences, or Teva Pharmaceutical? PR Newswire NEW YORK, Aug. 18, 2022 NEW...